Exercise and obesity in fibromyalgia: Beneficial roles of IGF-1 and resistin?

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Bjersing, Jan L ^a,b   Erlandsson, Malin ^a   Bokarewa, Maria I ^a,b   Mannerkorpi, Kaisa ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROPEPTIDE Y; RESISTIN; SOMATOMEDIN C;

ADULT; AEROBIC EXERCISE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXERCISE INTENSITY; FATIGUE; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HORMONE BLOOD LEVEL; HUMAN; KINESIOTHERAPY; LEAN BODY WEIGHT; LONGITUDINAL STUDY; MULTIDIMENSIONAL FATIGUE INVENTORY GENERAL FATIGUE; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; THERAPY EFFECT; TREATMENT DURATION; WALKING; BLOOD; CEREBROSPINAL FLUID; CLINICAL TRIAL; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MIDDLE AGED;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE THERAPY; FATIGUE; FEMALE; FIBROMYALGIA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MIDDLE AGED; OBESITY; RESISTIN;

EID: 84874259604     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4187     Document Type: Article

References (77)

1. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000, 160:221-227. 10.1001/archinte.160.2.221, 10647761.
2. Mease P, Clauw D, Christensen R, Crofford L, Gendreau R, Martin SA, Simon LS, Strand V, Williams DA, Arnold LM, OMERACT Fibromyalgia Working Group Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol 2011, 38:1487-1495. 10.3899/jrheum.110277, 3426365, 21724721, OMERACT Fibromyalgia Working Group.
3. Staud R. Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases. Curr Rheumatol Rep 2012, 14:539-548. 10.1007/s11926-012-0277-z, 22802155.
4. Mannerkorpi K, Gard G. Hinders for continued work among persons with fibromyalgia. BMC Muskuloskeletal Disorders 2012, 13:96.
5. Nicassio P, Moxham E, Schumand C, Gevirtz R. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain 2002, 100:271-279. 10.1016/S0304-3959(02)00300-7, 12467998.
6. Bennet RM, Jones J, Turk DC, Russel IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disorders 2007, 8:27.
7. Neumann L, Lerner E, Glazer Y, Bolotin A, Shefer A, Buskila D. A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life and physical functioning in fibromyalgia patients. Clin Rheumatol 2008, 27:1543-1547. 10.1007/s10067-008-0966-1, 18622575.
8. Okifuji A, Bradshaw DH, Olson C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms and functions. Clin Rheumatol 2009, 28:475-478. 10.1007/s10067-009-1094-2, 2668698, 19172342.
9. Kim CH, Luedtke CA, Vincent A, Thompson JM, Oh TH. Association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care Res 2012, 64:222-228.
10. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index and risk of fibromyalgi: longitudinal data from the Norwegian Nord-Trondelag Health Study. Arthritis Care Res 2010, 62:611-617.
11. Okifuji A, Donaldson GW, Barck L, Fine PG. Relationship between fibromyalgia and obesity in pain function, mood and sleep. J Pain 2010, 11:1329-1337. 10.1016/j.jpain.2010.03.006, 2939916, 20542742.
12. Maloney EM, Boneva RS, Lin JM, Reeves WC. Chronic fatigue syndrome is associated with metabolic syndrome: results from a case-control study in Georgia. Metabolism 2010, 59:1351-1357. 10.1016/j.metabol.2009.12.019, 20102774.
13. Vahl N, Jørgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol 1997, 272:E1108-E1116.
14. Pijl H, Langendonk JG, Burggraaf J, Frölich M, Cohen AF, Veldhuis JD, Meinders AE. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab 2001, 86:5509-5515. 10.1210/jc.86.11.5509, 11701729.
15. Faupel-Badger JM, Berrigan D, Ballard-Barbash R, Potischman N. Anthropometric corelates of insulin-like growth factor 1 (IGF-1) and IGF-1 binding protein-3 (IGFBP-3) levels by race/ethnicity and gender. Ann Epidemiol 2009, 19:841-849. 10.1016/j.annepidem.2009.08.005, 2786816, 19944347.
16. Friedrich N, Jørgensen T, Juul A, Spielhagen C, NaucK M, Wallaschofski H, Linneberg A. Insulin-like growth factor I and anthropometric parameters in a Danish population. Exp Clin Endocrinol Diabetes 2012, 120:171-174.
17. Bjersing JL, Dehlin M, Erlandsson M, Bokarewa MI, Mannerkorpi K. Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides. Arthr Res Ther 2012, 14:R162.
18. Jones KD, Deodhar P, Lorentzen A, Bennett RM, Deodhar AA. Growth hormone perturbations in fibromyalgia: a review. Semin Arthritis Rheum 2007, 36:357-379. 10.1016/j.semarthrit.2006.09.006, 17224178.
19. Cuatrecasas G, Alegre C, Fernandez-Sola J, Gonzalez MJ, Garcia-Fructuoso F, Poca-Dias V, Nadal A, Navarro F, Mera A, Lage M, Peino R, Casanueva F, Linan C, Sesmilo G, Coves MJ, Izquierdo JP, Alvarez I, Granados E, Puig- Domingo M. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain 2012, 153:1382-1389. 10.1016/j.pain.2012.02.012, 22465047.
20. Garcia-Segura LM, Diz-Chaves Y, Perez-Martin M, Darnaudéry M. Estradiol, insulin-like growth factor-I and brain aging. Psychoneuroendocrinology 2007, 32:S57-S61.
21. Morgado C, Silva L, Pereira-Terra P, Tavares I. Changes in serotonergic and noradrenergic descending pain pathways during painful diabetic neuropathy: the preventive action of IGF1. Neurobiol Dis 2011, 43:275-284. 10.1016/j.nbd.2011.04.001, 21515376.
22. Arwert LI, Veltman DJ, Deijen JB, van Dam PS, Delemarre-van deWaal HA, Drent ML. Growth hormone deficiency and memory functioning in adults visualized by functional magnetic resonance imaging. Neuroendocrinology 2005, 82:32-40. 10.1159/000090123, 16330884.
23. Thundyil J, Pavloski D, Sobey CG, Arumugam TV. Adiponectin receptor signalling in the brain. Br J Pharmacol 2012, 165:313-327. 10.1111/j.1476-5381.2011.01560.x, 3268187, 21718299.
24. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 2002, 8:1288-1295. 10.1038/nm788, 12368907.
25. Bassi M, do Carmo JM, Hall JE, da Silva AA. Chronic effects of centrally administered adiponectin on appetite, metabolism and blood pressure regulation in normotensive and hypertensive rats. Peptides 2012, 37:1-5. 10.1016/j.peptides.2012.06.013, 22749987.
26. Hoyda TD, Samson WK, Ferguson AV. Adiponectin depolarizes parvocellular paraventricular nucleus neurons controlling neuroendocrine and autonomic function. Endocrinology 2009, 150:832-840. 2646535, 18948398.
27. Barbosa IG, Rocha NP, de Miranda AS, Magalhaes PV, Huguet RB, de Souza LP, Kapczinski F, Teixeira AL. Increased levels of adipokines in bipolar disorder. J Psychiatr Res 2012, 46:389-393. 10.1016/j.jpsychires.2011.11.010, 22137759.
28. Diniz BS, Teixeira AL, Campos AC, Miranda AS, Rocha NP, Talib LL, Gattaz WF, Forlenza OV. Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res 2012, 46:1081-1085. 10.1016/j.jpsychires.2012.04.028, 22633396.
29. Liu J, Guo M, Zhang D, Cheng S-Y, Liu M, Ding J, Scherer PE, Liu F, and Xin-Yun L. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci USA 2012, 109:12248-12253. 10.1073/pnas.1202835109, 3409774, 22778410.
30. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011, 22:259-265. 3130099, 21497511.
31. Krysiak R. The role of adipokines in connective tissue diseases. Eur J Nutr 2012, 51:513-528. 10.1007/s00394-012-0370-0, 3397228, 22584415.
32. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472-476. 10.1016/S0006-291X(02)02841-3, 12504108.
33. Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One 2006, 1:e31. 10.1371/journal.pone.0000031, 1762367, 17183659.
34. Kusminski CM, Scherer PE. The road from discovery to clinic: adiponectin as a biomarker of metabolic status. Nature 2009, 86:592-595.
35. Lau CH, Muniandy S. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study. Cardiovascular Diabetology 2011, 10:8. 10.1186/1475-2840-10-8, 3036610, 21251282.
36. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010, 14:1419-1431.
37. Boström EA, Svensson M, Andersson S, Jonsson I-M, Ekwall A-K H, Eisler T, Dahlberg LE, Smith U, Bokarewa MI. Resistin and insulin/insulin-like growth factor signaling in rheumatoid arthritis. Arthritis Rheum 2011, 63:2894-2904. 10.1002/art.30527, 21739426.
38. Zhang Y, Proenca P, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432. 10.1038/372425a0, 7984236.
39. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997, 389:374-377. 10.1038/38717, 9311777.
40. Chehab FF. Leptin as a regulator of adipose mass and reproduction. Trends Pharmacol Sci 2000, 21:309-314. 10.1016/S0165-6147(00)01514-5, 10918637.
41. Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA 2006, 103:1593-1598. 10.1073/pnas.0508901103, 1360555, 16423896.
42. Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu XY. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacology 2010, 207:535-545. 10.1007/s00213-009-1684-3, 19823809.
43. Satoh N, Ogawa Y, Katsuura G, Tsuji T, Masuzaki H, Hiraoka J, Okazaki T, Tamaki M, Hayase M, Yoshimasa Y, Nishi S, Hosoda K, Nakao K. Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats. Endocrinology 1997, 138:947-954. 10.1210/en.138.3.947, 9048594.
44. Delgado TC, Violante IR, Nieto-Charques L, Cerdan S. Neuroglial metabolic compartmentation underlying leptin deficiency in the obese ob/ob mice as detected by magnetic resonance imaging and spectroscopy methods. Journal of Cerebral Blood Flow & Metabolism 2011, 31:2257-2266. 10.1038/jcbfm.2011.134, 23483681.
45. Gao S, Zhu G, Gao X, Wu D, Carrasco P, Casals N, Hegardt FG, Moran TH, Lopaschuk GD. Important roles of brain-specific carnitine palmitoyltransferase and ceramide metabolism in leptin hypothalamic control of feeding. Proc Natl Acad Sci USA 2011, 108:9691-9696. 10.1073/pnas.1103267108, 3111271, 21593415.
46. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995, 377:530-532. 10.1038/377530a0, 7566151.
47. Haque Z, Akbar N, Yasmeen F, Haleem MA, Haleem DJ. Inhibition of Immobilization Stress-induced Anorexia, Behavioral Deficits and Plasma Corticosterone Secretion by Injected Leptin in Rats. Stress 2012, doi:10.3109/10253890.2012.73604.
48. Guo M, Huang TY, Garza JC, Chua SC, Lu XY. Selective deletion of leptin receptors in adult hippocampus induces depression-related behaviours. Int J Neuropsychopharmacol 2012, 29:1-11.
49. Maeda T, Kiguchi N, Kobayashi Y, Ikuta T, Ozaki M, Kishioka S. Leptin derived from adipocytes in injured peripheral nerves facilitates development of neuropathic pain via macrophage stimulation. Proc Natl Acad Sci USA 2009, 106:13076-13081. 10.1073/pnas.0903524106, 2722338, 19620723.
50. Malva JO, Xapelli S, Baptista S, Valero J, Agasse F, Ferreira R, Silva AP. Multifaces of neuropeptide Y in the brain - neuroprotection, neurogenesis and neuroinflammation. Neuropeptides 2012, 46:299-308. 10.1016/j.npep.2012.09.001, 23116540.
51. Anderberg UM, Liu Z, Berglund L, Nyberg F. Elevated plasma levels of neuropeptide Y in female fibromyalgia patients. Eur J Pain 1999, 3:19-30. 10.1016/S1090-3801(99)90185-4, 10700334.
52. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994, 37:1583-1592. 10.1002/art.1780371105, 7980669.
53. Di Franco M, Iannuccelli C, Alessandri C, Paradiso M, Riccieri V, Libri F, Valesini G. Autonomic dysfunction and neuropeptide Y in fibromyalgia. Clin Exp Rheumatol 2009, 27:S75-78.
54. Griep EN, Boersma JW, Lentjes EG, Prins AP, van der Korst JK, de Kloet ER. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998, 25:1374-1381.
55. Fletcher MA, Rosenthal M, Antoni M, Ironson G, Zeng XR, Barnes Z, Harvey JM, Hurwitz B, Levis S, Broderick G, Klimas NG. Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome. Behav Brain Funct 2010, 6:76. 10.1186/1744-9081-6-76, 3024290, 21190576.
56. Klimas NG, Broderick G, Fletcher MA. Biomarkers for chronic fatigue. Brain, Behaviour, and Immunity 2012, 26:1202-1210.
57. Irwin MR. Human psychoneuroimmunology: 20 years of discovery. Brain behav 2008, 22:129-139.
58. Russel IJ, Orr MD, Litman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593-1601. 10.1002/art.1780371106, 7526868.
59. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomen in patients with fibromyalgi: new features for diagnosis. Pain 1988, 32:21-26. 10.1016/0304-3959(88)90019-X, 2448729.
60. Liu Z, Welin M, Bragee B, Nyberg F. A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides 2000, 21:853-860. 10.1016/S0196-9781(00)00219-9, 10959008.
61. Giovengo SL, Russel IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564-1569.
62. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia - increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012, 242:33-38. 10.1016/j.jneuroim.2011.10.013, 22126705.
63. Mannerkorpi K, Nordeman L, Cider T, Jonsson G. Does moderate-to-high aerobic exercise result in better improvement of body impairments and pain than low-intensive exercise in FM? A prospective randomised controlled trial. Arthritis Res Ther 2010, 12:R189. 10.1186/ar3159, 2991024, 20942911.
64. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172. 10.1002/art.1780330203, 2306288.
65. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991, 18:728-733.
66. Ericsson A, Mannerkorpi K. Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil 2007, 30:1665-1670.
67. Srikuea R, Symons TB, Long DE, Lee JD, Shang Y, Chomentowski PJ, Yu G, Crofford LJ, Peterson CA. Fibromyalgia is associated with altered skeletal muscle characteristics which may contribute to post-exertional fatigue in post-menopausal women. Arthritis Rheum 2012, 65:519-528.
68. Carville S, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsøe B, Dincer F, Henriksson C, Henriksson KG, Kosek E, Longley K, McCarthy GM, Perrot S, Puszczewicz M, Sarzi-Puttini P, Silman A, Späth M, Choy EH; EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Annals Rheum Dis 2008, 67:536-541.
69. Mannerkorpi K, Nordeman L, Ericsson A, Arndorw M, GAU-Study-Group Pool-exercise for patients with fibromyalgia or chronic widespread pain. A randomized controlled trial and subgroup analyses. J Rehabil Med 2009, 41:751-760. 10.2340/16501977-0409, 19774310, GAU-Study-Group.
70. Kim CH, Luedtke CA, Vincent A, Thompson JM, Oh TH. Association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care Res 2012, 64:222-228.
71. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index and risk of fibromyalgi: longitudinal data from the Norwegian Nord-Trondelag Health Study. Arthritis Care Res 2010, 62:611-617.
72. Choy E, Arnold L, Clauw D, Crofford L, Glass J, Simon L, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 2009, 36:2330-2334. 10.3899/jrheum.090368, 3412585, 19820222.
73. Bennett RM. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep 2002, 4:306-312. 10.1007/s11926-002-0039-4, 12126582.
74. Kohno D, Yada T. Neuropeptides. Arcuate NPY neurons sense and integrate peripheral metabolic signals to control feeding. Neuropeptides 2012, 46:315-319. 10.1016/j.npep.2012.09.004, 23107365.
75. Garcia-Segura LM, Rodriguez JR, Torres-Aleman I. Localization of the insuli-like growth factor I receptor in the cerebellum and hypothalamus of adult rats: an electron microscopic study. J Neurocytology 1997, 26:479-490.
76. Fernandez-Galas MC, Naftolin F, Garcia-Segura LM. Phasic synaptic remodeling of the rat arcuate nucleus during the estrous cycle depends on insulin-like growth factor-I receptor activation. J Neurosci Res 1999, 55:286-292. 10.1002/(SICI)1097-4547(19990201)55:3<286::AID-JNR3>3.0.CO;2-4, 10348659.
77. Singhal NS, Lazar MA, Ahima RS. Central resistin induces insulin resistance via neuropeptide Y. J Neurosci 2007, 27:12924-12932. 10.1523/JNEUROSCI.2443-07.2007, 18032666.